Polish clinical trials market poised to grow by 5% in 2010

In 2010, the clinical trials market in Poland is expected to grow by 5% year on year, and to reach 718 million zlotys ($240.9 million), according to the latest report by local market research firm PMR, entitled 'Clinical trials in Poland 2010 - Development forecasts for 2010-2012'. If barriers to market growth, including unclear legislation and difficult trial registration procedures at the Central Register of Clinical Trials (the CEBK), were removed, the clinical trials market could develop even more rapidly.

The clinical trials market in Poland slowed in 2009, in comparison with previous years. Between 2006 and 2008, it grew at a rate of 8%-10% per annum, whereas 2009 saw a year-on-year increase of only 1%, based on PMR estimates. 'This poor market growth rate was, evidently, caused by the economic crisis, as a result of which companies cut down on expenditure on R&D projects, including clinical trials. On the other hand, the market is already quite saturated, which is why, according to us, it is not expected to grow at an exponential rate in the future,' says Agnieszka Stawarska, a PMR pharmaceutical market analyst and the report co-author. PMR forecasts that in 2010 the market will expand by around 5% year on year and will be worth 718 million zlotys.

Work on Clinical Trials Act still in progress